Skip to content

Rafael Holdings, Inc. RFL Other Income (Expense)

Other Income (Expense) at other companies

Intel logo
IntelINTC
-$738M-327%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$7.34M-313%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$3.85M+42.8%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-$2.84M-177%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
-$734K-159%

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+189%
P/S174×+93.5×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s other income (expense)?
Rafael Holdings, Inc. (RFL) reported other income (expense) of -$25K in Q1 2026.
How has Rafael Holdings, Inc.'s other income (expense) changed year-over-year?
Rafael Holdings, Inc.'s other income (expense) decreased by 116.2% year-over-year, from $154K to -$25K.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.